These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26721189)

  • 21. Invention and business performance in the tissue-engineering industry.
    Pangarkar N; Hutmacher DW
    Tissue Eng; 2003 Dec; 9(6):1313-22. PubMed ID: 14670118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 23. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
    Yamanaka T; Kano S
    Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
    Sklan A
    Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug patents and intellectual property rights.
    Raj GM; Priyadarshini R; Mathaiyan J
    Eur J Clin Pharmacol; 2015 Apr; 71(4):403-9. PubMed ID: 25640303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Early achievements of the Danish pharmaceutical industry-6 Pharmacia].
    Grevsen JV; Kruse E; Kruse PR
    Theriaca; 2014; (42):9-30. PubMed ID: 25816560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patenting nanotechnology.
    Lemley MA
    Stanford Law Rev; 2005 Nov; 58(2):601-30. PubMed ID: 16395838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential.
    Euh Y; Lee D
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33503944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney.
    Melethil S
    AAPS J; 2005 Oct; 7(3):E723-8. PubMed ID: 16353948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patent cliff mitigation strategies: giving new life to blockbusters.
    Kakkar AK
    Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patent nonsense: evidence tells of an industry out of social control.
    Mintzberg H
    CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
    [No Abstract]   [Full Text] [Related]  

  • 32. Patent owner options for correcting errors in US patents after grant.
    Armstrong M
    Pharm Pat Anal; 2014 Sep; 3(5):499-508. PubMed ID: 25374319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fragmentation in the biopharmaceutical industry.
    Goldsmith AD; Varela FE
    Drug Discov Today; 2017 Feb; 22(2):433-439. PubMed ID: 27816494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protecting new ideas and inventions in nanomedicine with patents.
    Bawa R; Bawa SR; Maebius SB; Flynn T; Wei C
    Nanomedicine; 2005 Jun; 1(2):150-8. PubMed ID: 17292072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A thing patented is a thing divulged: Francis E. Stewart, George S. Davis, and the legitimization of intellectual property rights in pharmaceutical manufacturing, 1879-1911.
    Gabriel JM
    J Hist Med Allied Sci; 2009 Apr; 64(2):135-72. PubMed ID: 19151419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indian pharma enters the global arena.
    Singh S
    Cell; 2007 Mar; 128(5):811-4. PubMed ID: 17350563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of pharma R&D productivity - a new perspective needed.
    Schuhmacher A; Hinder M; von Stegmann Und Stein A; Hartl D; Gassmann O
    Drug Discov Today; 2023 Oct; 28(10):103726. PubMed ID: 37506762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry.
    Dierks RM; Bruyère O; Reginster JY; Richy FF
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):571-578. PubMed ID: 27653356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major advances in globalization and consolidation of the artificial insemination industry.
    Funk DA
    J Dairy Sci; 2006 Apr; 89(4):1362-8. PubMed ID: 16537967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of the leading patent equivalents services.
    Johns TM; Andrus WG; De Voe S; Myers J; Smith RG; Uhlir O
    J Chem Inf Comput Sci; 1979 Nov; 19(4):241-6. PubMed ID: 551974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.